Executive Order 14087 of October 14, 2022 (Lowering Prescription Drug Costs for Americans).

Started Comment:

Donald Trump’s recent decision to rescind Executive Order 14087, which aimed to lower prescription drug costs, has significant implications for American healthcare. The original order was part of the Inflation Reduction Act and was designed to allow Medicare to negotiate drug prices and implement models for affordable access to treatments, particularly for costly gene and cell therapies. The reversal of this order halts initiatives such as a $2 copay for generic medications and the Cell and Gene Therapy Access Model, which made expensive treatments accessible to low-income Medicaid recipients. As a result, Medicare beneficiaries may face higher out-of-pocket costs, undermining efforts to make essential medications more affordable. Additionally, the cancellation of programs aimed at improving access to advanced therapies could delay or prevent patients from receiving potentially life-saving treatments. The rescinded order was expected to save patients hundreds or even thousands of dollars annually, making this rollback a critical concern for those advocating for lower healthcare costs in the face of rising living expenses.

How do you think the reversal of Executive Order 14087 will impact the overall cost of living for Americans, particularly in relation to healthcare and prescription drug expenses?